Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6504429 | 0.93 | KMT2A (0.49) | RXFP1POLBTP53HDAC1KMT2A | |
| SCHEMBL6504903 | 0.87 | KMT2A (0.49) | HDAC1KMT2AMEN1KDM4EABCB1 | |
| SCHEMBL6498598 | 0.86 | KMT2A (0.53) | RXFP1POLBTP53HDAC1KMT2A | |
| SCHEMBL6500262 | 0.84 | KMT2A (0.48) | RXFP1POLBHDAC1KMT2AMEN1 | |
| SCHEMBL6504732 | 0.83 | HDAC1 (0.48) | POLBTP53HDAC1KMT2AMEN1 | |
| SCHEMBL6506101 | 0.83 | KMT2A (0.52) | POLBTP53HDAC1KMT2AMEN1 | |
| SCHEMBL6510133 | 0.83 | ABCB1 (0.44) | RXFP1POLBTP53HDAC1KMT2A | |
| SCHEMBL6504692 | 0.83 | HDAC1 (0.47) | HDAC1KMT2AMEN1MAPTABCB1 | |
| SCHEMBL6470160 | 0.78 | HDAC1 (0.43) | POLBTP53HDAC1KMT2AMEN1 | |
| SCHEMBL6505525 | 0.76 | ITK (0.43) | POLBHDAC1KMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | PHARMACIA AND UPJOHN COMPANY LLC | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | IL4, ARG2, CASP4 | RXFP1 843/4885POLB 2941/4885TP53 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.